Afthentopoulos I E, Passadakis P, Oreopoulos D G, Bargman J
Toronto Western Hospital, Ontario, Canada.
Adv Ren Replace Ther. 1998 Jul;5(3):157-67. doi: 10.1016/s1073-4449(98)70028-7.
Sclerosing peritonitis (SP) is a severe life-threatening condition for patients undergoing continuous ambulatory peritoneal dialysis (CAPD). This report reviews our experience and that reported in the literature concerning the prevalence of SP in CAPD patients, predisposing factors, and in particular, the role of peritonitis, its clinical presentation, diagnosis, treatment, and prevention. A total of 1,288 end-stage renal disease (ESRD) patients entered our peritoneal dialysis (PD) program between September 1977 and September 1997, seven of whom (0.54%) developed SP. The annual incidence of SP was 0.37 per 1,000 patient years, male-to-female ratio was 2.5 (M/F:5/2), mean age was 39+/-16 (median, 37; range, 23 to 61) years, and the median duration on CAPD was 62 (range, 12 to 144) months. Five patients were on CAPD for > or =4 years and two for less than 4 years before they were diagnosed with SP. All SP patients presented with clinical symptoms suggestive of intestinal obstruction, and five patients had decreased solute or fluid removal and had to increase the daily dialysate volume (3/7) or the tonicity of the fluid (4.25%) (3/7) or to combine a regular hemodialysis (HD) session with CAPD (2/7). There was a mean weight loss of 5+/-6 (median, 2; range, 0 to 18) kg. All patients had an episode of peritonitis at a mean time of 2+/-1 (median, 1; range, 1 to 3) months before the diagnosis of SP. The peritonitis was due to Staphylococcus aureus in four and Staphylococcus epidermidis, fungi, and Escherichia coli in one each. The definitive diagnosis of SP was established by laparotomy in four patients or postmortem examination in one patient, while in the remaining two there was no surgical confirmation; however, we believe the diagnosis was extremely likely because of the presence of clinical and radiologic criteria for SP. After the diagnosis of SP, all patients had their catheters removed, CAPD was discontinued permanently, and they were transferred to HD. Although there are isolated case reports of successful outcomes after surgical intervention, especially in patients in whom a peritoneal "cocoon" is related to severe peritonitis, usually the prognosis following surgery is poor. Treatment with immunosuppressive agents has been reported to be beneficial in the treatment of SP, although this has not been confirmed by all investigators. Among our SP patients, five (72%) died of sepsis (3/5) in a mean period of 10+/-5 (median, 9; range, 6 to 17) months after the diagnosis of SP and two are still alive on HD. SP is a rare but serious complication of CAPD. Severe peritonitis, especially in patients on dialysis for more than 4 years, may lead to SP As the prevalence of SP increases in patients on long-term CAPD, early detection is important because of the high morbidity and mortality associated with this condition.
硬化性腹膜炎(SP)对于接受持续性非卧床腹膜透析(CAPD)的患者而言是一种严重的、危及生命的病症。本报告回顾了我们的经验以及文献中所报道的关于CAPD患者中SP的患病率、易感因素,特别是腹膜炎的作用、其临床表现、诊断、治疗及预防。1977年9月至1997年9月期间,共有1288例终末期肾病(ESRD)患者进入我们的腹膜透析(PD)项目,其中7例(0.54%)发生了SP。SP的年发病率为每1000患者年0.37例,男女比例为2.5(男/女:5/2),平均年龄为39±16(中位数为37;范围为23至61)岁,CAPD的中位持续时间为62(范围为12至144)个月。5例患者在被诊断为SP之前接受CAPD治疗≥4年,2例患者接受CAPD治疗不足4年。所有SP患者均表现出提示肠梗阻的临床症状,5例患者溶质或液体清除减少,不得不增加每日透析液量(3/7)或液体的张力(4.25%)(3/7)或联合定期血液透析(HD)与CAPD(2/7)。平均体重减轻5±6(中位数为2;范围为0至18)kg。所有患者在诊断SP前平均2±1(中位数为1;范围为1至3)个月有一次腹膜炎发作。腹膜炎由金黄色葡萄球菌引起的有4例,表皮葡萄球菌、真菌和大肠杆菌引起的各1例。4例患者通过剖腹手术、1例患者通过尸检确诊为SP,其余2例未得到手术证实;然而,由于存在SP的临床和影像学标准,我们认为诊断极有可能。诊断SP后,所有患者均拔除导管,永久停止CAPD,并转至HD治疗。尽管有孤立的病例报告显示手术干预后有成功的结果,特别是在腹膜“茧”与严重腹膜炎相关的患者中,但通常手术后的预后较差。据报道,免疫抑制剂治疗对SP的治疗有益,尽管并非所有研究者都证实了这一点。在我们的SP患者中,5例(72%)在诊断SP后平均10±5(中位数为9;范围为6至17)个月死于败血症(3/5),2例仍在HD治疗下存活。SP是CAPD一种罕见但严重的并发症。严重的腹膜炎,特别是透析4年以上的患者,可能导致SP。随着长期CAPD患者中SP的患病率增加,由于这种病症相关的高发病率和死亡率,早期检测很重要。